The FDA accused Eli Lilly and Co. of “misleading” marketing, issued a formal warning letter, and asked them to stop publishing and distributing a brochure about the drug Alimta. If Lilly does not resolve the issue the FDA may decide to impose various penalties on the company. Federal officials reported that Lilly “omits material facts and risk information essential to the safe and effective use” of Alimta. Physicians prescribe this drug to treat mesothelioma and some forms of lung cancer.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.